KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group - PubMed (original) (raw)
Comparative Study
. 2006 Mar 1;107(5):1806-9.
doi: 10.1182/blood-2005-08-3408. Epub 2005 Nov 15.
Affiliations
- PMID: 16291592
- DOI: 10.1182/blood-2005-08-3408
Free article
Comparative Study
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group
Akira Shimada et al. Blood. 2006.
Free article
Abstract
Patients with t(8;21) acute myeloid leukemia (AML) are considered to have a good prognosis; however, approximately 50% of them relapse. The genetic alterations associated with a poor outcome in t(8;21) AML remain unknown. Recently, aberrations of receptor tyrosine kinases (RTKs) were frequently found in patients with AML. However, the prevalence and prognostic impact of RTK aberrations in pediatric t(8;21) AML remains undetermined. Here, we found the kinase domain mutations of the KIT gene in 8 (17.4%) of 46 patients with t(8;21) AML among newly diagnosed pediatric patients with AML treated on the AML99 protocol in Japan. Significant differences between patients with or without KIT mutations were observed in the 4-year overall survival (50.0% versus 97.4%, P = .001), disease-free survival (37.5% versus 94.7%, P < .001) and relapse rate (47.0% versus 2.7%, P < .001). Furthermore, FLT3 internal tandem duplication was found in only 2 (4.3%) patients. These results suggested that KIT mutations are strongly associated with a poor prognosis in pediatric t(8;21) AML.
Similar articles
- High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, Tsuchida M, Horibe K, Tsukimoto I, Adachi S, Kojima S, Hayashi Y. Shimada A, et al. Int J Hematol. 2012 Oct;96(4):469-76. doi: 10.1007/s12185-012-1163-1. Epub 2012 Aug 23. Int J Hematol. 2012. PMID: 22915059 - Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K, Inokuchi K. Wakita S, et al. Leukemia. 2011 Sep;25(9):1423-32. doi: 10.1038/leu.2011.104. Epub 2011 May 24. Leukemia. 2011. PMID: 21606963 - Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ, Zhu HH, Jiang Q, Jiang H, Zhang LP, Xu LP, Wang Y, Liu YR, Lai YY, Shi HX, Jiang B, Huang XJ. Qin YZ, et al. Leuk Res. 2014 Dec;38(12):1435-40. doi: 10.1016/j.leukres.2014.09.017. Epub 2014 Oct 6. Leuk Res. 2014. PMID: 25449688 Clinical Trial. - Clinical implications of molecular genetic aberrations in acute myeloid leukemia.
Scholl S, Fricke HJ, Sayer HG, Höffken K. Scholl S, et al. J Cancer Res Clin Oncol. 2009 Apr;135(4):491-505. doi: 10.1007/s00432-008-0524-x. Epub 2009 Jan 6. J Cancer Res Clin Oncol. 2009. PMID: 19125300 Review. - Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S, Chi S, Minami Y, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Morishita T, Kondo T, Yanada M, Yamamoto K, Kuroda J, Usuki K, Akahane D, Gotoh A. Katagiri S, et al. Int J Mol Sci. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694. Int J Mol Sci. 2022. PMID: 35563085 Free PMC article. Review.
Cited by
- High temporal resolution prediction of mortality risk for single AML patient via deep learning.
Lei Y, Wei H, Gao X. Lei Y, et al. iScience. 2024 Jul 5;27(8):110458. doi: 10.1016/j.isci.2024.110458. eCollection 2024 Aug 16. iScience. 2024. PMID: 39108717 Free PMC article. - Prognostic Factors of Pediatric Acute Myeloid Leukemia Patients with t(8;21) (q22;q22): A Single-Center Retrospective Study.
Yang J, Zhu X, Zhang H, Fu Y, Li Z, Xing Z, Yu Y, Cao P, Le J, Jiang J, Li J, Wang H, Zhai X. Yang J, et al. Children (Basel). 2024 May 17;11(5):605. doi: 10.3390/children11050605. Children (Basel). 2024. PMID: 38790600 Free PMC article. - Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.
Hayashi Y, Harada Y, Harada H. Hayashi Y, et al. Leukemia. 2022 May;36(5):1203-1214. doi: 10.1038/s41375-022-01548-7. Epub 2022 Mar 30. Leukemia. 2022. PMID: 35354921 Review. - Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.
Yamato G, Kawai T, Shiba N, Ikeda J, Hara Y, Ohki K, Tsujimoto SI, Kaburagi T, Yoshida K, Shiraishi Y, Miyano S, Kiyokawa N, Tomizawa D, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Taga T, Horibe K, Ogawa S, Hata K, Hayashi Y. Yamato G, et al. Blood Adv. 2022 Jun 14;6(11):3207-3219. doi: 10.1182/bloodadvances.2021005381. Blood Adv. 2022. PMID: 35008106 Free PMC article. - Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.
Kaburagi T, Yamato G, Shiba N, Yoshida K, Hara Y, Tabuchi K, Shiraishi Y, Ohki K, Sotomatsu M, Arakawa H, Matsuo H, Shimada A, Taki T, Kiyokawa N, Tomizawa D, Horibe K, Miyano S, Taga T, Adachi S, Ogawa S, Hayashi Y. Kaburagi T, et al. Haematologica. 2022 Mar 1;107(3):583-592. doi: 10.3324/haematol.2020.269431. Haematologica. 2022. PMID: 33730843 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous